MMAF is a potent inhibitor of tubulin polymerization. MMAF works by blocking the process of tubulin polymerization, disrupting the intracellular microtubule network, thereby inhibiting cell division and inducing apoptosis[1-2]. MMAF can be used as a cytotoxic component in antitumor drugs and antibody-drug conjugates[3-4].
References:
[1] Yamazaki CM, Yamaguchi A, Anami Y, et al. Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat Commun. 2021 Jun 10;12(1):3528. doi: 10.1038/s41467-021-23793-7.
[2] Nishigaki T, Takahashi T, Serada S, et al. Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer. Br J Cancer. 2020 Apr;122(9):1333-1341.
[3] Vire B, Skarzynski M, Thomas JD, et al. Harnessing the fcμ receptor for potent and selective cytotoxic therapy of chronic lymphocytic leukemia. Cancer Res. 2014 Dec 15;74(24):7510-7520.
[4] Yao X, Jiang J, Wang X, et al. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity. Breast Cancer Res Treat. 2015 Aug;153(1):123-33.
MMAF一种有效的微管蛋白聚合抑制剂，MMAF通过阻断微管蛋白的聚合过程，破坏细胞内的微管网络，从而抑制细胞分裂并诱导细胞凋亡[1-2]。MMAF可被用作用作抗肿瘤药物、抗体偶联药物中的细胞毒性成分[3-4]。